Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18740390 | INTERLEUKIN 18 (IL-18) VARIANTS AND FUSION PROTEINS COMPRISING SAME | June 2024 | September 2024 | Allow | 3 | 0 | 1 | Yes | No |
| 18526598 | IL-15-BASED FUSIONS TO IL-12 AND IL-18 | December 2023 | February 2024 | Allow | 3 | 0 | 1 | Yes | No |
| 18501741 | DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10 | November 2023 | February 2024 | Allow | 4 | 0 | 1 | Yes | No |
| 18214282 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | June 2023 | October 2023 | Allow | 4 | 0 | 0 | Yes | No |
| 18176913 | USE OF G-CSF ANTIBODY FOR TREATMENT OF PULMONARY FIBROSIS | March 2023 | May 2023 | Allow | 3 | 0 | 0 | Yes | No |
| 18176957 | SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODY | March 2023 | April 2023 | Allow | 2 | 0 | 0 | Yes | No |
| 18168428 | IL-15-BASED FUSIONS TO IL-12 AND IL-18 | February 2023 | October 2023 | Allow | 8 | 0 | 2 | Yes | No |
| 18162368 | HIGH CONCENTRATION ANTIBODY-CONTAINING LIQUID FORMULATION | January 2023 | May 2023 | Allow | 3 | 0 | 0 | Yes | No |
| 18060816 | INTERLEUKIN-18 VARIANTS AND METHODS OF USE | December 2022 | October 2023 | Allow | 10 | 0 | 1 | Yes | No |
| 17994223 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | November 2022 | March 2023 | Allow | 4 | 0 | 0 | Yes | No |
| 17915808 | IMMUNOSTIMULATING IL-2 ANALOGS | September 2022 | May 2023 | Allow | 7 | 0 | 1 | Yes | No |
| 17820980 | IL-15-BASED FUSIONS TO IL-12 AND IL-18 | August 2022 | January 2023 | Allow | 5 | 0 | 2 | Yes | No |
| 17877091 | QTY FC FUSION RECEPTOR PROTEINS | July 2022 | November 2023 | Allow | 16 | 1 | 1 | Yes | No |
| 17841349 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | June 2022 | August 2022 | Allow | 2 | 0 | 0 | Yes | No |
| 17752978 | HIGH CONCENTRATION ANTIBODY-CONTAINING LIQUID FORMULATION | May 2022 | November 2022 | Allow | 5 | 0 | 0 | Yes | No |
| 17739688 | SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODY | May 2022 | February 2023 | Allow | 9 | 1 | 2 | Yes | No |
| 17722328 | TGF-Beta Polypeptides | April 2022 | January 2023 | Allow | 9 | 0 | 1 | Yes | No |
| 17717740 | METHODS OF MAKING AND USING EXTRACELLULAR DOMAIN-BASED CHIMERIC PROTEINS | April 2022 | April 2024 | Allow | 24 | 0 | 0 | Yes | No |
| 17711723 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | April 2022 | June 2022 | Allow | 2 | 0 | 0 | Yes | No |
| 17696028 | METHODS OF TREATING ATOPIC DERMATITIS | March 2022 | February 2024 | Allow | 23 | 1 | 1 | Yes | No |
| 17684460 | ANTI-PLASMA KALLIKREIN ANTIBODIES | March 2022 | June 2024 | Allow | 27 | 0 | 0 | Yes | No |
| 17684907 | BIOPHARMACEUTICAL COMPOSITIONS | March 2022 | May 2022 | Allow | 2 | 0 | 0 | Yes | No |
| 17684346 | HV1 MODULATORS AND USES | March 2022 | April 2024 | Allow | 26 | 0 | 1 | Yes | No |
| 17588949 | Advanced Avatar Dendritic Cells | January 2022 | May 2024 | Allow | 27 | 0 | 0 | Yes | No |
| 17587751 | ANTIBODY TO HUMAN IL-1 BETA | January 2022 | April 2024 | Allow | 26 | 0 | 0 | Yes | No |
| 17585126 | METHODS AND COMPOSITIONS FOR NATURAL KILLER CELLS | January 2022 | April 2024 | Allow | 27 | 0 | 1 | Yes | No |
| 17580038 | INTERLEUKIN-2 AGENTS AND USES THEREOF | January 2022 | November 2023 | Abandon | 22 | 0 | 1 | Yes | No |
| 17578265 | ENGINEERED IL-2 Fc FUSION PROTEINS | January 2022 | March 2024 | Allow | 26 | 0 | 1 | Yes | No |
| 17575438 | COMBINATION THERAPY FOR TREATMENT OF CORONARY ARTERY DISEASE | January 2022 | June 2024 | Abandon | 29 | 0 | 1 | No | No |
| 17574101 | NK-LYSIN PEPTIDE COMPOSITIONS AND METHODS FOR THEIR USE AS ANTIMICROBIAL/ANTIVIRAL AGENTS | January 2022 | May 2022 | Allow | 4 | 0 | 1 | Yes | No |
| 17574479 | MULTI-FUNCTIONAL AND MULTI-VALENT INTERLEUKIN-TGF-BETA RECEPTOR FUSION POLYPEPTIDES | January 2022 | June 2022 | Allow | 5 | 1 | 2 | Yes | No |
| 17571117 | INTERLEUKIN-31 MONOCLONAL ANTIBODIES FOR VETERINARY USE | January 2022 | May 2024 | Allow | 28 | 0 | 1 | Yes | No |
| 17561510 | ANTI-TGF-BETA ANTIBODIES AND THEIR USE | December 2021 | March 2024 | Allow | 27 | 0 | 1 | No | No |
| 17556208 | MOLECULES THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | December 2021 | June 2024 | Abandon | 29 | 0 | 1 | No | No |
| 17549785 | HIGH CONCENTRATION FORMULATIONS OF ANTI-CSF1 AND ANTI-CSF1R ANTIBODIES | December 2021 | April 2022 | Allow | 4 | 0 | 0 | Yes | No |
| 17530786 | LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOF | November 2021 | February 2022 | Allow | 3 | 0 | 0 | Yes | No |
| 17530150 | TREATMENT OR PREVENTION METHOD OF RADIATION DAMAGE BY ADMINISTRATION OF IL-5 RECEPTOR ALPHA CHAIN BINDING ANTIBODY | November 2021 | February 2024 | Allow | 27 | 0 | 1 | Yes | No |
| 17525421 | HUMAN IL-23 ANTIGEN BINDING PROTEINS | November 2021 | April 2024 | Allow | 29 | 0 | 0 | Yes | No |
| 17523432 | ACTIVATABLE INTERLEUKIN-2 POLYPEPTIDES AND METHODS OF USE THEREOF | November 2021 | September 2022 | Allow | 10 | 1 | 2 | Yes | No |
| 17519069 | ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODIES | November 2021 | February 2024 | Allow | 27 | 0 | 1 | Yes | No |
| 17516082 | Anti-IL-6 Antibody | November 2021 | April 2024 | Allow | 29 | 0 | 0 | Yes | No |
| 17451332 | CANCER TREATMENT BY BLOCKING HOST-INDUCED IL-1 IN COMBINATION WITH RADIOTHERAPY | October 2021 | November 2023 | Allow | 25 | 0 | 1 | Yes | No |
| 17504100 | IL-15-BASED FUSIONS TO IL-7 AND IL-21 | October 2021 | March 2024 | Allow | 29 | 0 | 0 | Yes | No |
| 17492440 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | October 2021 | February 2022 | Allow | 5 | 0 | 1 | Yes | No |
| 17486683 | IL-15-BASED FUSIONS TO IL-12 AND IL-18 | September 2021 | November 2022 | Allow | 13 | 0 | 1 | Yes | No |
| 17471466 | Compositions and Methods of Use of Alpha-1 Antitrypsin Fusion Polypeptides | September 2021 | December 2023 | Allow | 27 | 0 | 1 | Yes | No |
| 17470246 | SUPERAGONISTS AND ANTAGONISTS OF INTERLEUKIN-2 | September 2021 | February 2024 | Allow | 29 | 0 | 0 | Yes | No |
| 17465145 | MULTI-LEVEL SPECIFIC TARGETING OF CANCER CELLS | September 2021 | January 2024 | Allow | 28 | 0 | 1 | Yes | No |
| 17458028 | ANTIBODY CYTOKINE ENGRAFTED COMPOSITIONS AND METHODS OF USE FOR IMMUNOREGULATION | August 2021 | January 2024 | Abandon | 29 | 0 | 1 | No | No |
| 17403710 | ANTIBODY-CYTOKINE ENGRAFTED PROTEINS AND METHODS OF USE FOR IMMUNE RELATED DISORDERS | August 2021 | October 2023 | Allow | 26 | 0 | 1 | Yes | No |
| 17444598 | COMPOSITIONS AND METHODS FOR MACROPHAGE CONVERSION | August 2021 | January 2024 | Allow | 29 | 0 | 1 | Yes | No |
| 17388895 | THERAPEUTIC IL-13 POLYPEPTIDES | July 2021 | January 2024 | Allow | 30 | 0 | 0 | Yes | No |
| 17388322 | Anti-IL-33 Antibodies and Uses Thereof | July 2021 | March 2024 | Allow | 31 | 1 | 1 | Yes | No |
| 17386047 | IL-2 MUTEINS AND USES THEREOF | July 2021 | August 2023 | Allow | 25 | 0 | 0 | Yes | No |
| 17385714 | MULTIMERIC IL-15 SOLUBLE FUSION MOLECULES AND METHODS OF MAKING AND USING SAME | July 2021 | July 2023 | Allow | 24 | 0 | 0 | Yes | No |
| 17385061 | IL-2 MUTEINS AND USES THEREOF | July 2021 | July 2023 | Allow | 24 | 0 | 0 | Yes | No |
| 17373412 | BIOPHARMACEUTICAL COMPOSITIONS | July 2021 | November 2021 | Allow | 4 | 0 | 0 | Yes | No |
| 17373537 | BIOPHARMACEUTICAL COMPOSITIONS | July 2021 | December 2021 | Allow | 5 | 0 | 0 | Yes | No |
| 17373223 | BIOPHARMACEUTICAL COMPOSITIONS | July 2021 | November 2021 | Allow | 4 | 0 | 0 | Yes | No |
| 17363260 | ANTIBODIES AND POLYPEPTIDES DIRECTED AGAINST CD127 | June 2021 | October 2023 | Allow | 28 | 0 | 1 | Yes | No |
| 17353987 | IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | June 2021 | January 2024 | Abandon | 30 | 0 | 1 | No | No |
| 17339810 | MASKED CYTOKINE POLYPEPTIDES | June 2021 | July 2023 | Allow | 25 | 0 | 0 | Yes | No |
| 17339801 | MASKED CYTOKINE POLYPEPTIDES | June 2021 | July 2023 | Allow | 25 | 0 | 0 | Yes | No |
| 17333256 | COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES | May 2021 | May 2023 | Allow | 24 | 0 | 0 | Yes | No |
| 17334341 | METHOD FOR TREATING RHEUMATOID ARTHRITIS WITH A HUMAN IL-6 RECEPTOR ANTIBODY AND METHOTREXATE | May 2021 | January 2023 | Abandon | 20 | 2 | 1 | No | No |
| 17326009 | Induction of IL-12 using immunotherapy | May 2021 | September 2023 | Allow | 28 | 0 | 1 | Yes | No |
| 17320779 | ACTIVATABLE INTERLEUKIN-2 POLYPEPTIDES AND METHODS OF USE THEREOF | May 2021 | January 2024 | Allow | 32 | 0 | 1 | Yes | No |
| 17314198 | ANTI-GM-CSF ANTIBODIES | May 2021 | January 2024 | Abandon | 32 | 0 | 1 | No | No |
| 17245679 | ACTIVATABLE IL2 COMPOSITION AND METHODS OF USE | April 2021 | November 2022 | Allow | 18 | 0 | 1 | Yes | No |
| 17241609 | Anti-IL1RAP Antibodies and Their Use for Treating Humans | April 2021 | June 2023 | Allow | 25 | 0 | 0 | Yes | No |
| 17240260 | HLA-A24 AGONIST EPITOPES OF MUC1-C ONCOPROTEIN AND COMPOSITIONS AND METHODS OF USE | April 2021 | May 2023 | Allow | 25 | 0 | 0 | Yes | No |
| 17232979 | ANTIBODIES AGAINST IL-7R ALPHA SUBUNIT AND USES THEREOF | April 2021 | October 2023 | Allow | 30 | 0 | 1 | Yes | No |
| 17284693 | Marrow Infiltrating Lymphocytes With Increased Clonality and Uses Thereof | April 2021 | October 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17226506 | METHOD OF TREATING AUTOIMMUNE DISEASE WITH LYMPHOCYTE ANTIGEN CD5-LIKE (CD5L) PROTEIN | April 2021 | August 2023 | Allow | 29 | 0 | 1 | Yes | No |
| 17213483 | NK-LYSIN PEPTIDE COMPOSITIONS AND METHODS FOR THEIR USE AS ANTIMICROBIAL/ANTIVIRAL AGENTS | March 2021 | October 2021 | Allow | 7 | 0 | 2 | Yes | No |
| 17212270 | Bi-Specific Fusion Proteins | March 2021 | June 2023 | Allow | 27 | 0 | 1 | Yes | No |
| 17210878 | QTY FC FUSION RECEPTOR PROTEINS | March 2021 | March 2022 | Allow | 12 | 0 | 1 | Yes | No |
| 17210837 | QTY FC FUSION WATER SOLUBLE RECEPTOR PROTEINS | March 2021 | September 2022 | Allow | 17 | 2 | 0 | Yes | No |
| 17211180 | HETERODIMERIC PROTEINS AND USES THEREOF | March 2021 | August 2023 | Allow | 29 | 0 | 1 | Yes | No |
| 17208064 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | March 2021 | August 2023 | Allow | 29 | 0 | 1 | Yes | No |
| 17207272 | INTERLEUKIN-1 INHIBITION FOR COMBINATION TREATMENT OF PANCREATIC CANCER CACHEXIA | March 2021 | June 2023 | Allow | 27 | 0 | 1 | Yes | No |
| 17201350 | IL-2 MUTEINS AND USES THEREOF | March 2021 | June 2023 | Allow | 27 | 0 | 0 | Yes | No |
| 17196451 | COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE | March 2021 | December 2023 | Abandon | 33 | 1 | 0 | No | No |
| 17274460 | SINGLE-DOMAIN ANTIBODIES AGAINST CLL1 AND CONSTRUCTS THEREOF | March 2021 | March 2024 | Allow | 37 | 0 | 0 | Yes | No |
| 17172109 | GREMLIN-1 CRYSTAL STRUCTURE AND INHIBITORY ANTIBODY | February 2021 | June 2023 | Allow | 29 | 0 | 1 | Yes | No |
| 17166441 | IL-7R-ALPHA BINDING COMPOUNDS | February 2021 | October 2021 | Allow | 9 | 2 | 0 | Yes | No |
| 17158785 | FUSION PROTEIN COMPRISING IL13 | January 2021 | January 2022 | Allow | 11 | 0 | 3 | Yes | No |
| 17151860 | ANTI-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF | January 2021 | August 2023 | Allow | 31 | 0 | 1 | Yes | No |
| 17150789 | REGULATING IL-4 AND IL-13 LEVELS BY BLOCKING HIGH AFFINITY BINDING BY IL-3, IL-5 AND GM-CSF TO THEIR COMMON RECEPTOR | January 2021 | December 2023 | Abandon | 35 | 1 | 0 | No | No |
| 17150691 | IL-1Beta Neutralizing Human Monoclonal Antibodies | January 2021 | March 2023 | Allow | 26 | 0 | 0 | Yes | No |
| 17150689 | IL-1Beta Neutralizing Human Monoclonal Antibodies | January 2021 | October 2023 | Allow | 33 | 1 | 0 | Yes | No |
| 17144537 | MODIFIED IL-2 POLYPEPTIDES AND USES THEREOF | January 2021 | October 2022 | Allow | 22 | 0 | 1 | Yes | No |
| 17129100 | Interleukin 15 Protein Complex and Use Thereof | December 2020 | March 2023 | Allow | 26 | 0 | 0 | Yes | No |
| 17128776 | METHODS AND COMPOSITIONS FOR TREATING MULTIPLE SCLEROSIS AND RELATED DISORDERS | December 2020 | July 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17254054 | CYTOKINE-BASED BIOACTIVATABLE DRUGS AND METHODS OF USES THEREOF | December 2020 | December 2022 | Allow | 24 | 0 | 1 | Yes | No |
| 17124930 | IMMUNE-STIMULATING HUMANIZED MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-2, AND FUSION PROTEINS THEREOF | December 2020 | August 2023 | Allow | 32 | 0 | 1 | Yes | No |
| 17121375 | METHOD FOR IDENTIFYING ANTI-CANCER AGENTS USING AN IN VITRO CELL CULTURE SYSTEM THAT MAINTAINS CANCER CELL STEMNESS | December 2020 | April 2023 | Allow | 28 | 0 | 0 | Yes | No |
| 17119923 | IL-2 ORTHOLOGS AND METHODS OF USE | December 2020 | January 2023 | Allow | 25 | 0 | 1 | Yes | No |
| 17115391 | SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODY | December 2020 | May 2023 | Allow | 30 | 1 | 0 | No | No |
| 17109924 | ANTI-GM-CSF ANTIBODIES AND USES THEREOF | December 2020 | November 2023 | Allow | 35 | 0 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MERTZ, PREMA MARIA.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 14.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MERTZ, PREMA MARIA works in Art Unit 1646 and has examined 1,151 patent applications in our dataset. With an allowance rate of 63.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 27 months.
Examiner MERTZ, PREMA MARIA's allowance rate of 63.5% places them in the 16% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MERTZ, PREMA MARIA receive 1.09 office actions before reaching final disposition. This places the examiner in the 16% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by MERTZ, PREMA MARIA is 27 months. This places the examiner in the 55% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +57.9% benefit to allowance rate for applications examined by MERTZ, PREMA MARIA. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 32.0% of applications are subsequently allowed. This success rate is in the 59% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 41.1% of cases where such amendments are filed. This entry rate is in the 56% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 68% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 80.0% of appeals filed. This is in the 68% percentile among all examiners. Of these withdrawals, 81.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 54.8% are granted (fully or in part). This grant rate is in the 69% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 7.2% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.